Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RIGL
stocks logo

RIGL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
66.44M
+15.36%
1.040
+30%
59.29M
+11.16%
0.695
+10.32%
65.75M
-35.34%
0.990
-69.82%
Estimates Revision
The market is revising Upward the revenue expectations for Rigel Pharmaceuticals, Inc. (RIGL) for FY2025, with the revenue forecasts being adjusted by 3.55% over the past three months. During the same period, the stock price has changed by 14.61%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.55%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.64%
In Past 3 Month
Stock Price
Go Up
up Image
+14.61%
In Past 3 Month
Wall Street analysts forecast RIGL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RIGL is 45.67 USD with a low forecast of 38.00 USD and a high forecast of 57.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast RIGL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RIGL is 45.67 USD with a low forecast of 38.00 USD and a high forecast of 57.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 47.380
sliders
Low
38.00
Averages
45.67
High
57.00
Current: 47.380
sliders
Low
38.00
Averages
45.67
High
57.00
Cantor Fitzgerald
Neutral
maintain
$32 -> $38
2025-11-05
Reason
Cantor Fitzgerald
Price Target
$32 -> $38
2025-11-05
maintain
Neutral
Reason
Cantor Fitzgerald raised the firm's price target on Rigel Pharmaceuticals to $38 from $32 and keeps a Neutral rating on the shares. The strong quarter on TAVALISSE $44.7M proved that the strong uptick we saw in Q3 wasn't a one-time fluke, the analyst tells investors in a research note. The firm thinks the pipeline opportunity deserves "equal attention" in light of the trends from TAVALISSE in 2025.
Jefferies
Hold
to
Buy
upgrade
$42
2025-11-05
Reason
Jefferies
Price Target
$42
2025-11-05
upgrade
Hold
to
Buy
Reason
Jefferies upgraded Rigel Pharmaceuticals to Buy from Hold with a $42 price target.
Jefferies
Hold -> Buy
upgrade
$23 -> $42
2025-11-05
Reason
Jefferies
Price Target
$23 -> $42
2025-11-05
upgrade
Hold -> Buy
Reason
As previously reported, Jefferies upgraded Rigel Pharmaceuticals to Buy from Hold with a price target of $42, up from $23, after Q3 product sales beat Street expectations and the company raised total 2025 net product sales guidance to $225M-$230M from $210M-$220M. The firm cites strong commercial execution, positive cash flow and room for potential business development for its upgrade.
Citigroup
Yigal Nochomovitz
Strong Buy
Maintains
$49 → $55
2025-03-06
Reason
Citigroup
Yigal Nochomovitz
Price Target
$49 → $55
2025-03-06
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$57
2025-03-05
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$57
2025-03-05
Reiterates
Strong Buy
Reason
B. Riley Securities
Kalpit Patel
Hold
Maintains
$20 → $24
2025-03-05
Reason
B. Riley Securities
Kalpit Patel
Price Target
$20 → $24
2025-03-05
Maintains
Hold
Reason
B. Riley raised the firm's price target on Rigel Pharmaceuticals to $24 from $20 and keeps a Neutral rating on the shares following the Q4 report. The upside was driven primarily by stronger than expected net product sales and an uptick in contract revenues from collaborations, the analyst tells investors in a research note. The firm increased estimates following the earnings report.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Rigel Pharmaceuticals Inc (RIGL.O) is 12.16, compared to its 5-year average forward P/E of -9.67. For a more detailed relative valuation and DCF analysis to assess Rigel Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.67
Current PE
12.16
Overvalued PE
31.52
Undervalued PE
-50.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-9.38
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
14.03
Undervalued EV/EBITDA
-32.79

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.80
Current PS
0.00
Overvalued PS
4.56
Undervalued PS
1.03
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

RIGL News & Events

Events Timeline

(ET)
2025-11-17
08:13:50
Rigel Pharmaceuticals' olutasidenib demonstrates effectiveness in Phase 2 trial for AML
select
2025-11-04 (ET)
2025-11-04
16:28:47
Rigel Pharmaceuticals increases FY25 revenue forecast to $285M-$290M, up from $270M-$280M
select
2025-11-04
16:26:46
Rigel Pharmaceuticals announces Q3 earnings per share of $1.46, surpassing consensus estimate of 94 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-26PRnewswire
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

  • Company Presentation: Rigel Pharmaceuticals' CFO, Dean Schorno, will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 8:30 am ET.

  • Access Information: The live webcast and archived recording of the presentation can be accessed through the Investor Relations section of Rigel's website.

  • Company Background: Rigel Pharmaceuticals, founded in 1996 and based in South San Francisco, focuses on developing therapies for hematologic disorders and cancer.

  • Contact Information: For investor and media inquiries, contact details for Rigel Pharmaceuticals and media representative David Rosen are provided.

[object Object]
Preview
9.0
11-19NASDAQ.COM
From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity?

  • Biotech Sector Performance: The biotech sector is experiencing significant stock surges and advancements in trials and regulatory filings, highlighting the importance of distinguishing between short-term price fluctuations and long-term value for investors.

  • Notable Stock Highlights: Several biotech companies, including Olema Pharmaceuticals, Owlet Inc., and Rigel Pharmaceuticals, have reached new 52-week highs, driven by positive trial results and strategic offerings.

  • Upcoming Developments: Companies like Jazz Pharmaceuticals and Tarsus Pharmaceuticals are preparing for important regulatory submissions and clinical trials, indicating ongoing innovation and potential market impact.

  • Financial Outlooks: Firms such as Natera and Kiniksa Pharmaceuticals have provided updated revenue guidance for 2025, reflecting growth expectations and strategic advancements in their respective fields.

[object Object]
Preview
9.0
11-17PRnewswire
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology

  • Efficacy and Safety of Olutasidenib: Olutasidenib has shown durable efficacy and a manageable safety profile in patients with relapsed or refractory mutant IDH1 acute myeloid leukemia (AML), including those previously treated with venetoclax, with a five-year follow-up confirming these findings.

  • Clinical Trial Updates: Rigel Pharmaceuticals has initiated a fifth study in collaboration with MD Anderson to further evaluate olutasidenib, and the first patient has been enrolled in the CONNECT TarGeT-D study, which assesses olutasidenib in combination with temozolomide for high-grade glioma patients.

  • Patient Outcomes: In a cohort of 147 patients, 35% achieved complete remission or partial hematologic recovery, with a median overall survival of 11.5 months, while those with fewer prior treatments had better outcomes.

  • Safety Profile Consistency: The five-year safety profile of olutasidenib remained consistent with previous reports, with no new safety signals identified, and differentiation syndrome was noted in 16% of patients, emphasizing the need for monitoring during treatment.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Rigel Pharmaceuticals Inc (RIGL) stock price today?

The current price of RIGL is 47.38 USD — it has increased 0.36 % in the last trading day.

arrow icon

What is Rigel Pharmaceuticals Inc (RIGL)'s business?

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.

arrow icon

What is the price predicton of RIGL Stock?

Wall Street analysts forecast RIGL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RIGL is 45.67 USD with a low forecast of 38.00 USD and a high forecast of 57.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Rigel Pharmaceuticals Inc (RIGL)'s revenue for the last quarter?

Rigel Pharmaceuticals Inc revenue for the last quarter amounts to 69.46M USD, increased 25.59 % YoY.

arrow icon

What is Rigel Pharmaceuticals Inc (RIGL)'s earnings per share (EPS) for the last quarter?

Rigel Pharmaceuticals Inc. EPS for the last quarter amounts to 1.46 USD, increased 108.57 % YoY.

arrow icon

What changes have occurred in the market's expectations for Rigel Pharmaceuticals Inc (RIGL)'s fundamentals?

The market is revising Upward the revenue expectations for Rigel Pharmaceuticals, Inc. (RIGL) for FY2025, with the revenue forecasts being adjusted by 3.55% over the past three months. During the same period, the stock price has changed by 14.61%.
arrow icon

How many employees does Rigel Pharmaceuticals Inc (RIGL). have?

Rigel Pharmaceuticals Inc (RIGL) has 162 emplpoyees as of December 05 2025.

arrow icon

What is Rigel Pharmaceuticals Inc (RIGL) market cap?

Today RIGL has the market capitalization of 860.01M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free